Open-label, Non-randomized, Single-center Study Investigating the Feasibility, Safety, Tolerability and Efficacy of Suizenji in Unresectable Pancreatic Ductal Adenocarcinoma Patients

This is a feasibility, safety, tolerability, and efficacy research study of an investigational device called "Suizenji", an ultrasound-guided high-intensity focused ultrasound (HIFU) therapy system for the treatment of unresectable pancreatic ductal adenocarcinoma. Focused ultrasound therapy uses a number of small ultrasound generators attached to a bowl-shaped ultrasound generator to emit ultrasound waves from outside to inside the body and focus them on a single point where cancerous cells in the pancreas are located. The targeted area is then heated, which kills the pancreatic cancer cells, and as a result, the patient's life may be prolonged. Experience with Suizenji for pancreatic cancer patients has shown that the "heating" is only a warm feeling in the abdomen during the treatment.

Start Date01 Dec 2025

Sponsor / Collaborator

Sonire Therapeutics Inc

NCT05700448

/ Not yet recruitingPhase 3

A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL)

The purpose of this study is to evaluate the efficacy and safety of sugemalimab (CS1001) in combination with PGemOx regimen (pegaspargase, gemcitabine, oxaliplatin) in treatment of adult patients with Extranodal NK/T-Cell Lymphoma (ENKTL) who have relapsed or become refractory to asparaginase-based regimens.

Start Date01 Dec 2025

Sponsor / Collaborator

CStone Pharmaceuticals Co. Ltd.

NCT07020065

/ Not yet recruitingPhase 2IIT

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% A Multicentre Randomized Open-label Phase II Trial

Metastatic non-small cell lung cancer is often treated with a combination of chemotherapy and immunotherapy. In patients over the age of 70, some are already in poor health and frail, requiring assistance with daily activities, for example. Older and/or frail individuals often do not tolerate standard-dose chemotherapy well, and their risk of side effects is higher than that of younger patients.
For this reason, the SAKK 18/24 study is investigating how effective and safe chemotherapy is in patients over 70 years of age when the chemotherapy drugs are administered at lower doses than usual. The aim of the study is to find a potentially effective and well-tolerated treatment for older people with metastatic non-small cell lung cancer.

Start Date01 Nov 2025

Sponsor / Collaborator

Swiss Group for Clinical Cancer Research

100 Clinical Results associated with Gemcitabine

100 Translational Medicine associated with Gemcitabine

100 Patents (Medical) associated with Gemcitabine

27,278

Literatures (Medical) associated with Gemcitabine

01 Mar 2026·BIOMATERIALS

Temperature-activated in situ hydrogel augments tumor treatment

Article

Author: Yang, Haojian ; Yu, Qianqian ; Yang, Ting ; Zhang, Cuiyun ; Wu, Qi ; Liu, Jihong ; Liang, Jiahui ; Wang, Qi ; Lin, Jiangtao ; Shi, Yiqi ; Xu, Shiyun ; Zhu, Wei-Hong ; Yao, Chenxing

In situ gels with tumor-targeted therapy often struggle with precise spatiotemporal drug release, compromising their efficacy in complex and heterogenous tumors. Here, we present a temperature-activated in situ hydrogel (PTT-Br@mPEG-PLGA and Gem@TCM-TK-PEG in chitosan and PF127 gel, denoted as PP + GC gel. Therein, the photothermal compound PTT-Br is fully named 6-bromo-1-ethyl-2-(2-(6-hydroxy-2,3-dihydro-1H-xanthen-4-yl)vinyl)quinolin-1-ium, while the reactive oxygen species (ROS)-responsive polymer TCM-TK-PEG is fully named tricyano methylene pyridine-thioketal-polyethylene glycol.) with the physiological temperature/photothermal/ROS-responsive drug store and release, thereby maximizing treatment outcomes. After intratumoral injection, PP + GC gel undergoes physiological temperature (37 °C)-responsive sol-gel phase transition, forming stable drug depot for enhanced tumor retention. Upon 635 nm laser irradiation, loaded photothermal agent converts light energy into heat (∼45 °C), triggering photothermal-responsive gel-sol phase transition for actively controlling encapsulated ROS-responsive therapeutic agents release, coupled with photothermal therapy. Subsequently, high levels of ROS in tumor cells disrupt the structure of ROS-responsive therapeutic agents, switching on the chemotherapeutic drug gemcitabine release and further stimulating immune response. Remarkably, laser irradiation of multiple short-duration induces a stronger immune response than that of single long-duration, thus achieving superior treatment outcomes. Benefiting from the smart control of photothermal therapy, chemotherapy, and immunotherapy, active PP + GC gel exhibits a tumor inhibition rate of approximately 82.25 % in melanoma-bearing mouse models, demonstrating significant antitumor efficacy while maintaining excellent biosafety.

01 Feb 2026·BIOMATERIALS

Mitocytosis-inducing nanoparticles alleviate gemcitabine resistance via dual disruption of pyrimidine synthesis and redox homeostasis in pancreatic ductal adenocarcinoma

Article

Author: Song, Haolin ; Sun, Tao ; Jiang, Chen ; Fan, Hongrui ; Cheng, Leilei ; Chen, Qinjun ; Su, Boyu ; Li, Xuwen ; Wang, Yu

Metabolic reprogramming in pancreatic ductal adenocarcinoma (PDAC) poses a significant challenge to the efficacy of gemcitabine-based chemotherapy. Aberrant activation of intracellular pyrimidine metabolism is a key factor contributing to the reduced effectiveness of gemcitabine. Combining gemcitabine with metabolic regulators targeting critical pathways may alleviate gemcitabine resistance. In this study, we focus on the abnormal activation of dihydroorotate dehydrogenase (DHODH) in PDAC cells, a pivotal enzyme in the de novo pyrimidine synthesis pathway that diminishes cellular sensitivity to gemcitabine and catalyzes the reduction of ubiquinone to ubiquinol, playing an essential role in maintaining cellular redox homeostasis. To address these challenges, we developed GE11 peptide-modified polyphenol-iron chelate nanoparticles for co-delivery the long carbon chain-modified gemcitabine and the DHODH inhibitor leflunomide, with peptide modification enabling nanoparticles to target PDAC cells with high expression of epidermal growth factor receptor. The nanoparticles demonstrated the ability to induce mitocytosis and achieve deep tumor penetration in PDAC tissues. Upon drug release at the core lesion, the three components, modified gemcitabine, leflunomide and iron ions synergistically enhanced tumor cell killing by alleviating gemcitabine resistance and disrupting cellular redox homeostasis to induce multimodal cell death. In an in situ pancreatic cancer mouse model, this strategy exhibited superior anti-tumor efficacy compared to the standard AG chemotherapy regimen (nab-paclitaxel and gemcitabine), even at a 6.3-fold lower gemcitabine concentration. These findings underscore the potential of this approach as a highly effective therapeutic strategy for PDAC treatment.

31 Dec 2025·Molecular & Cellular Oncology

CHK1 inhibition overcomes gemcitabine resistance in non-small cell lung cancer cell A549

Article

Author: Ma, Xuan ; Liang, Ai-Ling ; Fu, Tian ; Wang, Wen-Xuan ; Ke, Zhi-Yin ; Wang, Xue-Chun ; Liu, Yong-Jun ; Yin, Hai-Han

The purpose of the study is mainly to investigate anti proliferation of non-small cell lung cancer A549 cells and its mechanism by inhibition of CHK1 expression combined with gemcitabine. The mRNA and protein levels of genes were analyzed by RT-qPCR and Western blot, respectively. Cell viability was detected by CCK-8 assay and clone formation assay. The detection of the cell cycle was used by Annexin V/7-amino-actinomycin D apoptosis detection kit. Analysis of DNA damage was done by immunofluorescence and alkaline comet assay. The results showed that inhibition of CHK1 and gemcitabine combination significantly reduced the proliferation ability of the two cell lines. We also revealed the degradation of full-length PARP and reduced Bcl-2/Bax ratio on increased apoptosis. Inhibition of CHK1 expression leads to DNA damage, induces phosphorylation of γ-H2AX, and affects the repair of homologous recombination ability through Rad51. Mechanistically, gemcitabine increased phosphorylation-ATR and phosphorylation-CHK1, indicating activation of the DNA repair system and ATR-CHK1-CDC25A pathway. Inhibition of CHK1 resulted in increased synthesis of CDK2/Cyclin A2 and CDK2/Cyclin E1 complexes, and more cells entered the subsequent cell cycle, leading to S phase arrest and mitotic catastrophe. We identified inhibition of CHK1 as a potential treatment for NSCLC and confirmed that inhibition of this kinase could overcome acquired gemcitabine resistance.

924

News (Medical) associated with Gemcitabine

11 Sep 2025

·endpoints.news

Revolution’s lead RAS blocker heads into Phase 3 in frontline pancreatic cancer after early data

Revolution Medicines said it will begin a late-stage test of its lead asset as a first-line treatment for a form of pancreatic cancer, after a Phase 1 study in this setting yielded promising data. The early-stage trial studied daraxonrasib in patients with treatment-naïve RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC). The drug works by inhibiting a protein called RAS that causes unchecked cell growth. The trial investigated the candidate as both monotherapy and in combination with chemotherapy. In the monotherapy cohort of 38 evaluable patients given a 300 mg daily oral dose of daraxonrasib, the objective response rate (ORR) was 47% , and the disease control rate (DCR) was 89%, Revolution said on Wednesday. As of the cutoff date of July 28, most patients remained on treatment, with a median follow-up of 9.3 months. Meanwhile, in the chemo combo arm, daraxonrasib was dosed at 200 mg per day with gemcitabine nab-paclitaxel (GnP) given every two weeks. In 31 patients with sufficient follow-up, the ORR was 55% and the DCR was 90%, with a median follow-up of 6.9 months. Revolution’s stock $RVMD ticked up by as much as 9% before market open on Thursday. Based on these data, the drugmaker is planning to start a global Phase 3 trial in first-line metastatic PDAC towards the end of this year. Dubbed RASolute 303, the trial will have monotherapy and GnP combo arms, which will be compared with a GnP control arm. In the combo arm, the Phase 3 trial will dose daraxonrasib at 200 mg per day, plus GnP, for six months, followed by 300 mg per day as monotherapy, according to a company presentation . Revolution also shared an update from a trial of daraxonrasib in the second-line RAS-mutant PDAC setting. As of June 30, a 300 mg daily pill resulted in ORRs of 35% and 29% in patients with a RAS G12X mutation or any RAS mutation, respectively. DCRs were 92% and 95%, in those respective groups. The median OS was 13.1 months in the RAS G12X mutant patients and 15.6 months in participants with any RAS mutation. Progression-free survival was 8.5 and 8.1 months, respectively. Median follow-up was 16.7 months. OS “compares very favorably” to the six to seven months seen in historic chemo trials, analysts from Jefferies wrote in a Wednesday note. The analysts said that the first-line PDAC opportunity is bigger and underappreciated compared with the second-line setting, where daraxonrasib is already in a pivotal trial and could yield data next year. Another pivotal trial, called RASolute 304, is planned for the fourth quarter of this year and will test daraxonrasib in the adjuvant setting. And the drug is also being tested in non-small cell lung cancer. Revolution recently formed a funding pact with Royalty Pharma for up to $2 billion, which should allow it to fund this suite of late-stage studies.

Clinical ResultPhase 3Phase 1Phase 2Clinical Trial Termination

10 Sep 2025

·www.fiercepharma.com

J&J's 'practice-changing' bladder cancer therapy Inlexzo lands FDA nod

With an 82% complete response rate seen in trials, Johnson & Johnson has touted high market hopes for the med. The FDA has signed off on Johnson & Johnson’s highly anticipated bladder cancer drug Inlexzo, marking an advance in the ability to care for patients who otherwise face bladder removal and limited treatment options.Inlexzo, previously called TAR-200, can now treat patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.The drug-releasing system combo allows for extended release of the chemotherapy gemcitabine directly to patients' bladders through an intravesical system that can be placed in minutes in an outpatient setting, with no general anesthesia needed, J&J said in a Sept. 9 release.Before the approval, the typical treatment route for NMIBC patients who don’t respond to standard-of-care BCG therapy was a radical cystectomy to remove the entire bladder. It's a life-altering and risky procedure that's not appropriate for many patients. J&J’s offering, meanwhile, provides a “potentially practice-changing” treatment, the company said.“We are proud of the science that has brought us to this historic moment,” John Reed, M.D., Ph.D., head of R&D at J&J Innovative Medicine, said in a statement. “As the only major healthcare company that hosts both pharmaceuticals and medical devices, we leveraged the speed and scale of Johnson & Johnson to accelerate innovation and deliver this important therapy to patients.”J&J picked up the asset from Taris Biomedical in 2019 with hopes to “give patients with bladder cancer a renewed sense of hope and belief,” Jennifer Taubert, J&J's head of Innovative Medicine, commented. “In an area that has seen little progress for more than 40 years, Inlexzo delivers a first-of-its-kind breakthrough innovation with a bright future ahead.” In a phase 2b study, 82% of Inlexzo-treated patients experienced a complete response without the need for reinduction, with 51% maintaining the response for at least one year. The complete response rate is the highest recorded among currently available therapies, Mark Wildgust, Ph.D., vice president of oncology global medical affairs for J&J Innovative Medicine, said in an interview with Fierce Pharma earlier this year.With its high complete response rate and its convenience factor, J&J believes Inlexzo will set itself apart from other bladder cancer offerings such as Merck’s Keytruda, Ferring Pharmaceuticals’ gene therapy Adstiladrin and ImmunityBio’s immunotherapy Anktiva, which is used alongside the BCG vaccine. The company has high hopes for the drug’s market potential.“In all the research that we have done, I have absolutely no reason to believe that they will use anything else but us once they fail BCG,” the president of J&J’s solid tumor business, Biljana Naumovic, told Fierce Pharma in April. She acknowledged, however, that the drug won’t reach that level of market dominance right away. J&J has already set up a patient support program and a Care Navigator offering educational resources at no cost to patients. Inlexzo is being further studied across patients with MIBC and those with NMIBC in four ongoing clinical trials.

Clinical ResultPhase 2ImmunotherapyVaccineDrug Approval

10 Sep 2025

·www.globenewswire.com

Relmada Issues Mid-Year CEO Letter to Shareholders

CORAL GABLES, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today issued a Letter to Shareholders from Sergio Traversa, Chief Executive Officer. Dear Fellow Shareholders: 2025 has been a truly transformational year for Relmada Therapeutics. With the year now well into its second half, I am pleased to share an update on our recent progress and to thank you for your continued support. Strategic Review and Portfolio Expansion Earlier this year, we completed a comprehensive strategic review that reaffirmed our mission to develop life-changing treatments while building a diversified portfolio. As a result, we added two differentiated Phase 2 product candidates that significantly strengthen Relmada’s long-term value proposition: NDV-01, a sustained-release formulation of gemcitabine and docetaxel in development for non-muscle invasive bladder cancer (NMIBC)Sepranolone, being developed for compulsivity disorders such as Prader-Willi Syndrome (PWS) NDV-01: Strong Phase 2 Results and Path to Phase 3 Six-month follow-up data from our Phase 2 study of NDV-01 demonstrated impressive results, with a 91% complete response (CR) rate at any time point following treatment. These findings build on the positive three-month data presented at the 2025 American Urological Association Annual Meeting and reinforce the potential of NDV-01 as a transformative, bladder-sparing therapy for NMIBC, a condition that affects approximately 600,000 patients in the U.S. We are actively preparing to initiate a Phase 3 registrational trial in the first half of 2026, with key activities underway including regulatory filings and manufacturing scale-up. Strengthening the NDV-01 Program To further support NDV-01, we added two experts in bladder cancer to the Relmada team: Raj S. Pruthi, MD as Chief Medical Officer–Oncology Yair Lotan, MD as Chair of the Clinical Advisory Board Their expertise will be invaluable as we advance the program toward late-stage development. Sepranolone: Advancing in Prader-Willi Syndrome Positive proof-of-concept data in Tourette’s syndrome suggest that sepranolone may hold promise as a therapy for compulsive disorders. In the first half of 2026, we plan to initiate a Phase 2 study in PWS, a rare genetic disorder affecting 350,000–400,000 people worldwide and characterized by compulsive behaviors such as hyperphagia (obsessive eating). Preparations, including regulatory engagement and manufacturing activities, are underway. Key Upcoming Milestones NDV-01 Phase 2 nine-month results (Q4 2025) and twelve months (Q1 2026)Product supply scale-up — 2H 2025U.S. IND clearance — 1H 2026Initiation of Phase 3 registrational trial — 1H 2026 Sepranolone FDA engagement and manufacturing activities — 2H 2025Initiation of Phase 2 PWS study — 1H 2026 Looking Ahead As we begin the autumn season, we remain optimistic about Relmada’s future. The progress of NDV-01 and sepranolone, combined with the expertise of our strengthened team, positions us well for value creation through disciplined execution and capital-efficient development. On behalf of the entire Relmada team, thank you for your continued trust and confidence. We look forward to keeping you updated on our progress in the months ahead. Sincerely, Sergio Traversa Chief Executive Officer Relmada Therapeutics, Inc. About Relmada Therapeutics, Inc. Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system conditions. Lead candidates NDV-01 and sepranolone are advancing through mid-stage clinical development with the potential to address significant unmet needs. For more information, visit www.relmada.com. Forward-Looking Statements: The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release/Shareholder Letter contains statements which constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “if”, “may”, “expects”, “anticipates”, “believes”, “will”, “will likely result”, “will continue”, “plans to”, “potential”, “promising”, and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the potential for Relmada’s product candidates to progress, including the potential for Phase 2 NDV-01 data to continue to deliver positive results supporting further development, the potential for clinical trials to deliver statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure to secure FDA agreement on the regulatory path for NDV-01, and sepranolone, or that future NDV-01, or sepranolone, clinical results will be acceptable to the FDA, failure to secure adequate NDV-10, or sepranolone, drug supply, and the other risk factors described under the heading “Risk Factors” set forth in the Company’s reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list. Investor Contact:Brian RitchieLifeSci Advisorsbritchie@lifesciadvisors.com Media Inquiries:Corporate Communicationsmedia@relmada.com

Phase 2Phase 3Clinical Result

100 Deals associated with Gemcitabine

External Link

KEGG	Wiki	ATC	Drug Bank
D02368	Gemcitabine	L01BC05	DB00441

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Cancer	Phase 3	-	RenovoRx, Inc.	01 Jun 2023
Metastatic Pancreatic Ductal Adenocarcinoma	Phase 3	Australia	Panbela Therapeutics, Inc.	04 Aug 2022
Locally Advanced Pancreatic Adenocarcinoma	Phase 3	United States	RenovoRx, Inc.	12 Mar 2018
Locally Advanced Pancreatic Adenocarcinoma	Phase 3	Belgium	RenovoRx, Inc.	12 Mar 2018
Advanced Lung Squamous Cell Carcinoma	Phase 3	United States	Sanofi	01 Mar 2010
Advanced Lung Squamous Cell Carcinoma	Phase 3	Belgium	Sanofi	01 Mar 2010
Advanced Lung Squamous Cell Carcinoma	Phase 3	Canada	Sanofi	01 Mar 2010
Advanced Lung Squamous Cell Carcinoma	Phase 3	France	Sanofi	01 Mar 2010
Advanced Lung Squamous Cell Carcinoma	Phase 3	Germany	Sanofi	01 Mar 2010
Advanced Lung Squamous Cell Carcinoma	Phase 3	Hungary	Sanofi	01 Mar 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2025	Not Applicable	Advanced biliary tract cancer First line	45	Cisplatin, Gemcitabine, Durvalumab	ljecufcvay(zngxrophuw) = jqyylisvdt debilckhhc (wmakrxespi ) View more	Positive	30 May 2025
NCT02807181 (SIRCCA, CTgov)	Phase 2/3	Unresectable Intrahepatic Cholangiocarcinoma	89	gemcitabine+Cisplatin (Chemotherapy (Cisplatin-Gemcitabine))	tztbyygeml(xziuycwcso) = ukvmuxaxfd lfkrxsaapu (wjudlloqyf, fvppstbxoq - jkhijraymp) View more	-	09 May 2025
NCT02807181 (SIRCCA, CTgov)	Phase 2/3	Unresectable Intrahepatic Cholangiocarcinoma	89	Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)+gemcitabine+Cisplatin (Radiation: SIRT + Chemotherapy (Cisplatin-Gemcitabine))	tztbyygeml(xziuycwcso) = ipnmbwgpob lfkrxsaapu (wjudlloqyf, skzbvdxhao - snmufmooyj) View more	-	09 May 2025
NCT04602078 (AUREA \| SOGUG-AUREA, CTgov)	Phase 2	Urothelial Carcinoma of the Urinary Bladder \| Locally Advanced Urothelial Carcinoma \| Metastatic urothelial carcinoma	82	Cisplatin 70 mg/m2+Gemcitabine 1000 mg/m2+Atezolizumab 1200 mg/m2	ykziqxfpkc = rdxbqweafe qekbzskrqc (uwguotqjdk, zbztyswqpa - vlmcmrfvtc) View more	-	24 Apr 2025
NCT01972919 (CTgov)	Phase 2	Pancreatic carcinoma non-resectable	23	Radiation Therapy+Gemcitabine+Capecitabine	jjmgfthgcg = txkixbvgdc qjocsvqufq (epgdffinjx, wmalfslnzq - twambmvawz) View more	-	10 Feb 2025
NCT04229004 (Precision Promise (PrP), ASCO_GI2025)	Phase 2/3	Metastatic Pancreatic Cancer Second line	317	Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA)	xfcwvqtoaj(quqmdamzjl): HR = 1.18 (95% CI, 0.88 - 1.56), P-Value = 0.14 View more	Negative	23 Jan 2025
NCT04229004 (Precision Promise (PrP), ASCO_GI2025)	Phase 2/3	Metastatic Pancreatic Cancer Second line	317	Gemcitabine/Abraxane (GA)		Negative	23 Jan 2025
NCT03257033 (TIGeR-PaC, ASCO_GI2025)	Phase 3	Locally Advanced Pancreatic Adenocarcinoma	19	Intra-arterial gemcitabine	bwqygzhaxn(ctxpathmrv) = wuytlwxbkb tfjbehpzjf (orbpzpbugo )	Positive	23 Jan 2025
NCT03257033 (TIGeR-PaC, ASCO_GI2025)	Phase 3	Locally Advanced Pancreatic Adenocarcinoma	19	Intravenous gemcitabine	bwqygzhaxn(ctxpathmrv) = luohfuighs tfjbehpzjf (orbpzpbugo )	Positive	23 Jan 2025
ACTRN12623000223639 (ASCO_GI2025)	Not Applicable	Advanced Pancreatic Ductal Adenocarcinoma	30	Gemcitabine + Nab-paclitaxel + LSTA-1 + Durvalumab	mbhaamnhlx(cbpbnoiefp) = xwbuvatisk rsshcwesdy (cgwhfbpmve )	Positive	23 Jan 2025
ASH2024	Not Applicable	Diffuse Large B-Cell Lymphoma	-	Glofitamab with Gemcitabine and Oxaliplatin	slgelifnoc(ohhjdgvmzp) = bhjqyffrqn yxcagejphf (hfsrmgodrk, NA) View more	-	09 Dec 2024
ASH2024	Not Applicable	Diffuse Large B-Cell Lymphoma	-	Rituximab with Gemcitabine and Oxaliplatin	slgelifnoc(ohhjdgvmzp) = rzmtecknsa yxcagejphf (hfsrmgodrk, NA) View more	-	09 Dec 2024
ASH2024	Not Applicable	Diffuse large B-cell lymphoma recurrent	-	R-GemOx	zkqlbcbrfo(yyrrpzentz) = lhcsejqcgc canjyiziob (dxmqemewyz, 16‒29) View more	-	07 Dec 2024
NCT04989218 (ICC, CTgov)	Phase 1/2	Intrahepatic Cholangiocarcinoma	1	Tremelimumab+Gemcitabine+Cisplatin+Durvalumab	kvxexkjolh = erwqrhdumw ryynxgploc (ycgzvvqbfp, cqjlelhfsl - eogomwtoub) View more	-	05 Nov 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis